Abstract Submission

Abstracts should be prepared strictly according to the following instructions. Non-adherence to the guidelines will lead to exclusion of your abstract. You can submit your abstract and edit until the submission deadline, but changes cannot be made after the abstract submission deadline. 

• 1 May, 2025 
  Abstract submission open
• 5 October, 2025*
  Late-breaking abstract Submission
• 10 November, 2025
  Notification of acceptance to authors
• 20 November, 2025
  Presenting author registration and payment deadline

* 23:59 h (UTC -5 o GMT-5)

• Abstracts must be submitted exclusively through the online abstract submission form available on this website. Abstracts submitted via email or by any other means will not be accepted. Abstracts received after the deadline will not be considered. The presenting author is responsible for ensuring that all co-authors are aware of the content of the abstract prior to submission.
• The Presenting author must be the Contact author in the submission form, and he/she must be listed first in the list of authors.
• All abstracts must be submitted in English. Please ensure you thoroughly check your submission for spelling and grammatical errors as accepted abstracts will be printed as per your submission.
• Abstracts must report on high quality research that has not been published in whole elsewhere and have not been previously presented at any international congress, including the WFNMB Congress.
• Clinical cases, case of interest or interesting images will not be accepted.
• The World Federation of Nuclear Medicine and Biology is dedicated to the promotion of evidence-based research and clinical observations. All abstracts are subject to peer review.
• All human or animal experimental studies presented must have prior Ethics Approval from institutional authorities. This must be declared in the Methods.
• No abbreviations or trade names are allowed neither in the title nor in the body of the abstract. However, the generic name may be used. 
• Multiple submissions by one author/author group covering the same study/results are not allowed and will result in rejection. However, submissions of different studies by the same author/author group are permitted. Each Presenting author can submit a maximum of three (3) abstracts. 

• The title should not exceed 20 words.
• Use lower case letters and only the first letter of the first word should be a capital letter.
• No full stop at the end of the title.
• The title of your e-poster should be identical to the title of the corresponding abstract.

Abstracts can be accepted as an oral presentation or e-poster. 

• The submitter must indicate their preferred presentation format as either “Oral or e-Poster” or “e-Poster only.” Selecting “e-Poster only” will automatically exclude the abstract from consideration for any oral sessions at the congress.
• All accepted e-Posters will be available for viewing in the on-site e-Poster Area, accessible to all participants.

Please select the most relevant topic for your abstract during submission. Please select the topic ‘others‘ in case your abstract does not fit to one of the proposed topics: 

• 1. Cardiology, Pulmonary
• 2. Endocrinology
• 3. Infection / Inflammation
• 4. Musculoskeletal
• 5. Neuroscience
• 6. Nuclear Medicine Innovation, Technology, Artificial Intelligence 
• 7. Oncology
• 8. Pediatrics
• 9. Physics (including instrumentation & dosimetry), Molecular imaging, Radiochemistry 
• 10. Genitourinary
• 11. Therapy
• 12. Others

Abstracts should have a minimum of 250 and a maximum of 300 words (references, title and authors details are not included in the word count.),

All abstracts must include the headings: 

• Background/Aims 
• Methods 
• Results 
• Conclusions

Abstracts may contain 1 graphic and 1 table. Abstracts should not contain bullet points. Please ensure any acronyms are spelt out in the first instance. 

• Insert the authors first name, last name and institute details as indicated on the online form. Do not add any titles or degrees: Prof., Dr., etc.
• The number of co-autors per abstract is limited to 10.
• The presenting author must register and pay for the WFNMB 2026 Congress by November 20, 2025, to ensure the abstract is included in the program and scheduled for presentation.
• All expenses related to the submission and presentation of an abstract (including airfare, accommodation, review fees, etc.) are the sole responsibility of the presenter.

All Conflict of Interest should be disclosed. 

Financial support received in regard to the work described should be acknowledged. 

All human or animal experimental studies presented must have prior Ethics Approval from institutional authorities. This must be declared in the Methods. 

Use generic drug names with the proprietary names in brackets e.g. xxx (yyy). Disclose the identity of experimental agents and/or technologies discussed. 

Avoid the use of trademarks, advertisements or product company logos. 

• You can include up to five references to previous publications.
• In the text body, publications should be cited as numbers between square brackets and referred to a consecutively, i.e. [1], [2], [3], [4] and [5].
• Authors are responsible for the accuracy of references. Only published articles and those in press (the journal should be stated) may be included; unpublished results and personal communications should be cited as such in the body text. 

An abstract is eligible for review when the abstract is submitted according to the guidelines on or before the deadline: 15 September 2025. All submitted abstracts will be evaluated by a scientific review committee. The author will be informed on the committee’s decision (acceptance for oral presentation, e-poster presentation or rejection) by e-mail no later than 20 November 2025.